PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.49%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-24.67%
G&A reduction while AXSM shows 45.59% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.97%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-17.97%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.31%
EBITDA growth below 50% of AXSM's 45.28%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Operating income growth below 50% of AXSM's 45.28%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
184.62%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
18.43%
Pre-tax income growth below 50% of AXSM's 43.58%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.43%
Net income growth below 50% of AXSM's 43.58%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
58.16%
EPS growth 1.25-1.5x AXSM's 44.32%. Bruce Berkowitz would examine sustainability.
58.16%
Diluted EPS growth 1.25-1.5x AXSM's 44.32%. Bruce Berkowitz would examine sustainability.
96.23%
Share count reduction below 50% of AXSM's 0.11%. Michael Burry would check for concerns.
96.23%
Diluted share reduction below 50% of AXSM's 0.11%. Michael Burry would check for concerns.